What changed
What changedPenumbra, Inc. reported its third-quarter results on October 29, 2026, recording a 7.8% decline in net income and an 8.5% drop in earnings per share (EPS) compared to the same period last year. Despite overall revenue growth, these figures indicate a shift in business profitability for the quarter.

Company history
October 2026
Penumbra Inc: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-29: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 410,145,000 USD (410 million); same period a year earlier (2025-07-01 to 2025-09-30): 354,685,000 USD (355 million); change +15.6% Source
- 2026-10-29: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 1,174,949,000 USD (1.2 billion; 1,175 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,018,280,000 USD (1 billion; 1,018 million); change +15.4% Source
- 2026-10-29: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 280,303,000 USD (280 million); same period a year earlier (2025-07-01 to 2025-09-30): 240,416,000 USD (240 million); change +16.6% Source
- 2026-10-29: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 798,658,000 USD (799 million); same period a year earlier (2025-01-01 to 2025-09-30): 680,309,000 USD (680 million); change +17.4% Source
- 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 50,739,000 USD (51 million); same period a year earlier (2025-07-01 to 2025-09-30): 48,838,000 USD (49 million); change +3.9% Source
- 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 130,012,000 USD (130 million); same period a year earlier (2025-01-01 to 2025-09-30): 130,016,000 USD (130 million); change 0% Source
- 2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 42,279,000 USD (42 million); same period a year earlier (2025-07-01 to 2025-09-30): 45,851,000 USD (46 million); change -7.8% Source
- 2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 109,674,000 USD (110 million); same period a year earlier (2025-01-01 to 2025-09-30): 130,344,000 USD (130 million); change -15.9% Source
- 2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 174,563,000 USD (175 million); same period a year earlier (2025-01-01 to 2025-09-30): 152,179,000 USD (152 million); change +14.7% Source
- 2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 42,320,000 USD (42 million); same period a year earlier (2025-01-01 to 2025-09-30): 45,295,000 USD (45 million); change -6.6% Source
- 2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 254,282,000 USD (254 million); previous balance (2025-12-31): 186,897,000 USD (187 million); change +36.1% Source
- 2026-10-29: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 1,583,509,000 USD (1.6 billion; 1,584 million); previous balance (2025-12-31): 1,427,603,000 USD (1.4 billion; 1,428 million); change +10.9% Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The merger with Boston Scientific Corporation is expected to close in early 2027.
Said October 29, 2026 · Period named: early 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 4,300,206 | $1,368,927,577 | +0.1% | Q3 2026 |
| State Street | 1,236,104 | $393,501,347 | -0.6% | Q3 2026 |
| Millennium Management | 1,039,025 | $330,763,219 | +48.3% | Q3 2026 |
| Geode Capital Management | 785,573 | $250,140,707 | -1.4% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 752,242 | $237,520,412 | — | Q2 2026 |
| Two Sigma Investments | 328,937 | $104,713,805 | -23.2% | Q3 2026 |
| Citadel Advisors | 252,696 | $80,443,245 | -43.7% | Q3 2026 |
| Soros Fund Management | 203,434 | $66,801,623 | — | Q1 2026 |
| D. E. Shaw & Co. | 146,773 | $46,723,716 | -25.6% | Q3 2026 |
| Fidelity (FMR) | 85,566 | $27,239,184 | -59.4% | Q3 2026 |
| Renaissance Technologies | 46,660 | $14,853,744 | -41.3% | Q3 2026 |
| Wellington Management | 20,388 | $6,437,511 | -6.5% | Q2 2026 |
| Bridgewater Associates | 1,474 | $469,233 | -6.7% | Q3 2026 |
| T. Rowe Price | 43,779 | $13,938 | -1.9% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.